GA enlargement, which was influenced by lesion features, was relentless, resulting in rapid central vision loss. Enlargement was significantly faster with ARMS2 risk (P < 0.0001), C3 non-risk (P = 0.0002), and APOE non-risk (P = 0.001) genotypes.Īnalyses of AREDS2 data on natural history of GA provide representative data on GA evolution and enlargement. In the combined group, GA enlargement was significantly faster with noncentrality, multifocality, intermediate baseline size, and bilateral GA (P < 0.0001 for interaction in each case) but not with AREDS2 treatment assignment (P = 0.33) or smoking status (P = 0.05). GA enlargement rate (following square root transformation) was similar in eyes with pre-existing GA (0.29 mm/year 95% confidence interval 0.27-0.30) and incident GA (0.28 mm/year 0.27-0.30).
In eyes with incident noncentral GA, 4-year risk of central involvement was 57%. In eyes with incident GA, 4-year risk of subsequent neovascular AMD was 29%. The Kaplan-Meier rate of incident GA was 19% of eyes at 5 years.
Of the remaining 6530 eyes at risk, 1099 eyes (17.3%) of 883 participants developed incident GA without prior neovascular disease during mean follow-up of 4.4 years. (1) Presence or development of GA (2) change in the square root of GA area over time.Īt baseline, 517 eyes (6.2%) of 411 participants (9.8%) had pre-existing GA (without neovascular AMD), with the following characteristics: 33% central, 67% noncentral and the following configurations: 36% small, 26% solid/unifocal, 24% multifocal, 9% horseshoe/ring, and 6% indeterminate. Analyses included GA prevalence and incidence rates, Kaplan-Meier rates, mixed-model regression, and multivariable analysis of the square root of GA, area adjusted for covariates, including clinical/imaging characteristics and genotype. Prospective cohort study within a controlled clinical trial.Īge-Related Eye Disease Study 2 (AREDS2) participants, aged 50-85 years.īaseline and annual stereoscopic color fundus photographs were evaluated for GA presence and area. To analyze the prevalence, incidence, and clinical characteristics of eyes with geographic atrophy (GA) in age-related macular degeneration (AMD), including clinical and genetic factors affecting enlargement.
0 kommentar(er)
